The content on this site is intended for healthcare professionals only
Sarah Cannon Research Institute research developments at ASCO 2010
The TOPICAL trial
Optimising adjuvant therapy in the treatment of early stage endometrial cancer patients
Costs and benefits of bone metastases therapies
Factors influencing the choice of bone metastases treatment
Targeted therapy for bone metastases
Key advances in ovarian cancer from ASCO 2010
The launch of Sarah Cannon Research UK and research developments at ASCO 2010
Early diagnosis of amyloidosis
Ovarian cancer research
Systemic therapy - what lies ahead?
An immunotherapy approach to pancreatic cancer
The PRIMA study
Biotherapy Development Association
PARP inhibitors
Advances in melanoma treatment
Potential biologic causes of the racial survival disparity seen in breast cancer
Advances in the treatment of melanoma
The role of radiotherapy in the treatment of locally advanced prostate cancer
Drug developments presented at ASCO 2010
Geriatric oncology
Phase III clinical trials at ASCO 2010
The ASCO/ECCO joint symposium
Breast cancer research from ASCO 2010
The impact of radiotherapy on patients with high risk localised prostate cancer
ALK mutation related non-small cell lung cancer
Targeted therapy in sarcoma treatment
Prognostic and predictive markers in breast cancer
Views on the joint ASCO-ASH education session
Views on the joint ASCO-ASH education session
The efficacy of denosumab and zoledronic acid as treatment for prostate cancer
Circulating tumour cells in breast cancer
The influence of zoledronic acid on the treatment of endocrine-responsive early breast cancer
Frontline treatments for lymphomas
Clinical trial Design: Comparator arms
New agent eribulin prolongs survival in metastatic breast cancer
Primary end points of clinical trials - overall survival versus progression free survival.
Results of the multiple myeloma study comparing zoledronic acid to clodronate
The efficacy of bendamustine and rituximab in the treatment of indolent lymphoma diseases
NKTR-102: a new drug for treating platinum-resistant or refractory ovarian cancer
Conatumumab or AMG 479 as treatment for pancreatic cancer
Roundup of the 2010 ASCO conference
Breast cancers that spread to the liver may change biology, impacting treatment effectiveness
Antibody drug ipilimumab improves long-term survival in previously treated advanced melanoma
ALK inhibitor shows high response rate in patients with advanced NSCLC harboring a specific gene alteration
New agent, eribulin, derived from marine sponge, increases survival among women with metastatic breast cancer
